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Parkinson’s disease (PD), the second most common age-associated progressive
neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons in
the substantia nigra pars compacta (SN). The pathogenesis of PD and the mechanisms
underlying the degeneration of DA neurons are still not fully understood. Our previous
quantitative proteomics study revealed that hyaluronan and proteoglycan binding link
protein 2 (Hapln2) is one of differentially expressed proteins in the substantia nigra
tissues from PD patients and healthy control subjects. However, the potential role of
Hapln2 in PD pathogenesis remains elusive. In the present study, we characterized the
expression pattern of Hapln2. In situ hybridization revealed that Hapln2mRNAwas widely
expressed in adult rat brain with high abundance in the substantia nigra. Immunoblotting
showed that expression levels of Hapln2 were markedly upregulated in the substantia
nigra of either human subjects with Parkinson’s disease compared with healthy
control. Likewise, there were profound increases in Hapln2 expression in neurotoxin
6-hydroxydopamine-treated rat. Overexpression of Hapln2 in vitro increased vulnerability
of MES23.5 cells, a dopaminergic cell line, to 6-hydroxydopamine. Moreover, Hapln2
overexpression led to the formation of cytoplasmic aggregates which were co-localized
with ubiquitin and E3 ligases including Parkin, Gp78, and Hrd1 in vitro. Endogenous
α-synuclein was also localized in Hapln2-containing aggregates and ablation of Hapln2
led to amarked decrease of α-synuclein in insoluble fraction comparedwith control. Thus,
Hapln2 is identified as a novel factor contributing to neurodegeneration in PD. Our data
provides new insights into the cellular mechanism underlying the pathogenesis in PD.
Keywords: hyaluronan and proteoglycan binding link protein 2, Parkinson’s disease, dopaminergic neurons,
ubiquitin-proteasome system, aggregation
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INTRODUCTION
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder affecting more than 1% of the
people aged over 65 years around the world (Delenclos et al.,
2016). It is mainly characterized by severe movement symptoms
including resting tremor, slowness of movement, rigidity and
postural instability (Kadoguchi et al., 2014; Delenclos et al.,
2016). Recent studies have shown that a number of significant
non-motor symptoms, such as depression, anxiety, sleep
disturbance, and pain, are also evident which appear to have
adverse impact on quality of life of patient with PD (Martinoia
et al., 2005). The economic burden of PD is projected to grow
substantially over the next few decades as the size of the elderly
population grows (Hirakawa et al., 2000). Pathologically, PD is
marked by the progressive loss of dopaminergic (DA) neurons
in the ventral midbrain and the formation of α-synuclein-
containing aggregates in neuronal cell bodies and neuritis
(Anderson et al., 2006; Kadoguchi et al., 2014). Although a large
variety of possible pathogenic factors, including excessive release
of oxygen free radicals during enzymatic dopamine breakdown,
impairment of mitochondrial function and calcium homeostasis,
dysregulation of LRRK2 kinase, neuroinflammation and loss of
trophic support, have been reported to contribute to the disease
processes, the etiology of PD has not yet been fully understood
(Block and Hong, 2005; Dick et al., 2007; Paumier et al., 2015;
Von Stockum et al., 2015), indicating the urgent need to identify
target of PD pathogenesis.
Emerging evidence indicates that abnormalities of some PD
related proteins, such as α-synuclein and parkin, play vital
roles during the progression of PD (Mukherjee et al., 2015;
Oliveira et al., 2015). Neural progenitor cell lines from PD
patient with α-synuclein overexpression exhibited a reduced
ability to differentiate into DA neurons (Oliveira et al., 2015).
Moreover, overexpression of wild-type or A53T mutated α-
synuclein by recombinant adeno-associated virus mediated-
overexpression in the rat substantia nigra (SN) induced the loss
of DA neurons and the formation of α-synuclein aggregation
(Lu et al., 2015). Interestingly, Parkin deficiency facilitated the
cell-to-cell transmission of α-synuclein (Cha et al., 2015). These
results suggest that investigation of the proteins involved in the
aggregates formation and in the neurodegeneration of nigral DA
neurons will provide new insights into the pathogenesis of PD
and may help identify new therapeutic targets.
In our previous efforts to characterize the proteome profiles
of nigral tissue of PD patients, we found that there were 11
proteins that showed significant alteration in expression levels in
the SN between the two cohorts (Liu et al., 2015). Among the
11 proteins, Hapln2 (also known as brain-derived link protein
1, Bral1) showed dramatic upregulation in the brain tissues of
PD patients compared with the healthy controls. Hapln2 is one
of the hyaluronan and proteoglycan binding link proteins, which
is consisted of four members: Hapln1 (also known as cartilage
link protein, Crtl1), Hapln2 (Bral1), Hapln3, and Hapln4 (Bral2)
(Spicer et al., 2003). Among these four link proteins, Hapln2 and
Hapln4 are preferentially expressed in the central nervous system
(Spicer et al., 2003). Hapln2 is important for stabilizing and
enhancing the binding of the four CSPG core proteins including
versican, BCAN, aggrecan, and NCAN to hyaluronan (Spicer
et al., 2003; Kähler et al., 2011).
The human HAPLN2 is encoded by four exons, consisting
of one immunoglobulin (Ig) fold and two proteoglycan tandem
repeat (PTR) domains (Hirakawa et al., 2000). Northern blot
analysis showed that Hapln2 mRNA was detected solely in
the adult human and mouse brains (Hirakawa et al., 2000).
Immunostaining also revealed that the expression of Hapln2
started at P20 in mice when axonal myelination took place
in the white matter and was predominantly expressed in
myelinated fiber tracts in the adult brain (Oohashi et al.,
2002). As one of the hyaluronan and proteoglycan binding link
proteins predominantly expressed in myelinated fiber tracts in
the adult brain, Hapln2 has been reported to play an important
role in maintaining and enhancing extracellular matrix (ECM)
structures and function in the formation of diffusion barrier
around the nodes of Ranvier and conduction velocity in mouse
brain (Spicer et al., 2003; Bekku et al., 2010; Kähler et al.,
2011). Hapln2 was co-localized with versican at the nodes of
Ranvier in the myelinated white matter (Oohashi et al., 2002).
Previous results showed that Hapln2-deficient mice exhibited
abnormal expression pattern of hyaluronan-associated ECM and
decrease of nerve conduction speed in the brain, indicating
the vital role of Hapln2 for neuronal conductivity (Bekku
et al., 2009, 2010). Moreover, accumulating evidence indicates
that Hapln2 is associated with brain disorders. The Hapln2
expression levels were remarkably reduced in schizophrenia
anterior temporal lobe (Neumann et al., 2009), while Hapln2
has been recently shown to be accumulated in the neurofibrillary
tangle of Alzheimer’s brain (Bandopadhyay, 2016). However, the
role of Hapln2 in the degeneration of DA neurons during PD
pathogenesis is totally unknown.
In the present study, we verified the upregulation of Hapln2 in
human PD brains using western blot. We also found that Hapln2
was markedly upregulated in the SN of 6-OHDA-induced rat
PD model. Overexpression of Hapln2 resulted in a profound cell
death of primary cultured neurons and MES23.5 cells in vitro.
Besides, immunofluorescence revealed that overexpression of
Hapln2 induced aggregates formation in which α-synuclein is
accumulated. Moreover, Hapln2 ablation led to a significant
decrease of the ratio of insoluble form to insoluble form of α-
synuclein in mouse brain. Our data demonstrated that Hapln2 is
involved in PD pathogenesis and the role of Hapln2 in PD may
be associated with ubiquitin-proteasome pathway (UPP).
MATERIALS AND METHODS
Human Tissue Collection
Fresh-frozen ventral mesencephalic tissues were obtained
from the Netherlands Brain Bank, Netherlands Institute for
Neuroscience, Amsterdam, the Netherlands. All the materials
have been collected from donors for or from whom a written
informed consent for a brain autopsy and the use of the
material and clinical information for research purposes had been
obtained by the Netherlands Brain Bank. Frozen brain tissues
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from three pairs of age and gender-matched PD patients and
healthy controls were used. Summary of the demographic and
clinicopathological data on the three PD and three control cases
used in this study were previously described by Liu et al. (2015).
Animals
Adult Sprague–Dawley rats (250–280 g) were purchased from
the Shanghai Laboratory Animal Center, Chinese Academy of
Sciences. Hapln2 knockout mice were a kind gift from Dr. T.
Oohashi (Bekku et al., 2010). The animals were maintained on
a 12 h light/dark cycle at 23◦C with food and water available
ad libitum. All the procedures were approved by the Institutional
Animal Care and Use Committee and were in accordance with
the US National Institutes of Health Guide for the Care and Use
of Laboratory Animals.
The 6-OHDA-Induced Rat PD Model
The 6-OHDA-induced rat model of PD was established as
described previously (Zhou et al., 2011). In brief, the adult rats
under deep anesthesia received a bilateral injection of 4µl of
6-OHDA (5µg/µl in sterile saline) in the striatum using the
coordinates relative to bregma (AP: +1.0mm, ML: −3.0mm,
DV: −5.0mm) with a Hamilton 10µl syringe at a rate of
0.5µl/min. The sham-lesioned rats served as controls were
injected with 4µl of sterile saline in the same region. The
needle was withdrawn slowly 5min following the completion
of injection. SN tissues were isolated for western blotting or
quantitative PCR 2 or 4 weeks post-surgery.
In situ Hybridization
In situ hybridization (ISH) was performed on cryosections
(15µm thick) with digoxigenin-labeled single-stranded RNA
probes as described previously (Zhou et al., 2011). Briefly, the
brain sections were fixed overnight in 4% paraformaldehyde
at 4◦C. To prepare the Hapln2 (GenBank accession number
AB049056) hybridization probes, primers were designed
to amplify a fragment with 300–400 bp. Sequences of the
primers used were as follow: forward, 5′-ACTAAGGCG
TGCCTATCAACT; reverse, 5′-CCACTTTGCTCCAGCGTA
C -3′. In some cases, brain sections were further processed
for tyrosine hydroxylase (TH, a marker for DA neurons)
immunohistochemistry using 3.3-diaminobenzidine (DAB,
Sigma-Aldrich, St. Louis, MO, USA) as substrate following
Hapln2 ISH. The sense probe was used as a negative control.
RNA Isolation and Quantitative RT-PCR
Isolation of total RNA was performed as described previously
(Shao et al., 2013). Briefly, total RNA was isolated from brain
tissues using TRIzol reagent (Invitrogen). Template cDNA was
synthesized from 1µg of extracted total RNA using PrimeScript
kit (TaKaRa, Japan) according to the manufacturer’s instruction.
Quantitative RT-PCR was carried out with SYBR-Green premix
Ex Taq (Takara, Japan) and detected by a Real Time PCR
System (Roche Light Cycler 480 or Rotorgene 6000, USA). Fold
changes were calculated using relative quantification methods
with β-actin as an internal control gene. The primers were
designed using Primer Picking Program and their sequences were
as follows: Hapln2, forward, 5′-ACTAAGGCGTGCCTATCA
ACT-3′, reverse, 5′-CCACTTTGCTCCAGCGTAC-3′; β-actin,
forward, 5′-ACCCGCCACCAGTTCGCCAT-3′, reverse, 5′-CTA
GGGCGGCCCACGATGGA-3′.
Extraction of RIPA-Soluble and
RIPA-Insoluble Protein Fractions of Mouse
Brain
Extraction of RIPA-soluble and RIPA-insoluble protein fractions
from brain tissues was described previously (Gallardo et al.,
2008; Neumann et al., 2009; Walker et al., 2015; Bandopadhyay,
2016). Previous studies indicated that separation of insoluble
fraction was performed on older mice at least 6 months of age
(Chandra et al., 2005; Ho et al., 2008). Six-month-old Hapln2
knockout or control mice were injected with LPS (5mg/kg, i.p.
Sigma-Aldrich) in order to enhance protein aggregation. The
brain tissues were isolated 24 h after LPS treatment and stored
at −20◦C prior to use. Frozen brain tissues were thawed on ice
and homogenized in 2× v/w RIPA buffer (150mM NaCl, 1%
Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 50mMNaF,
1mM EDTA,50mM Tris, pH 7.5). The lysates was centrifuged at
14,000 g at 4◦C for 30min and the supernatants were collected
as the RIPA-soluble fraction. The pellet was washed with RIPA
buffer and centrifuged at 14,000 g at 4◦C for 10min for 3 times.
The pellet was dissolved in 0.5× v/w urea buffer (8M urea,
100mM NaCl, 1Mm EDTA, 50mM Tris, PH 8) as urea-soluble
fraction.
Western Blot and Quantification
Western blotting was performed following standard procedures
as described previously (Li et al., 2006). The primary antibodies
used were detailed as follows: mouse monoclonal antibody
against Hapln2 (1:2000; Abnova); mouse monoclonal antibody
against β-actin (1:5000; Sigma-Aldrich); mouse anti-α-
tublin antibody (1:5000; Sigma-Aldrich). The membrane
was washed and incubated for 1 h at room temperature with
the corresponding secondary antibodies: horseradish peroxidase
(HRP)-conjugated goat anti-mouse IgG (1:10,000; Jackson
ImmunoResearch Laboratories, USA). Peroxidase activity was
detected with SuperSignal WestPico chemiluminescent substrate
(Pierce Biotechnology, USA). Immunoreactive bands were
visualized and digitized with ImageQuant (LAS-4000, Fujifilm,
Japan). Optical densities of bands were analyzed using ImageJ
software (NIH). The protein levels were normalized to loading
control of β-actin or α-tublin.
Immunofluorescence and
Immunohistochemistry
Immunofluorescence was performed as described previously
(Shao et al., 2013). Briefly, cryosections or fixed cell cultures
were blocked for 2 h in 5% goat serum diluted in phosphate
buffered saline with 0.5% Triton (PBST, pH7.4). The samples
were incubated with one primary antibody overnight at 4◦C
followed by incubation with secondary antibody conjugated
with either Alexa488 or Alexa555 (1:3000, Invitrogen) for 2 h
at room temperature. The same sections were then incubated
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with another primary antibody, followed by incubation with
the appropriate secondary antibody. Immunohistochemistry was
performed according to the procedure described previously (Liu
et al., 2015). In brief, brain sections were incubated with primary
antibody followed by biotinylated secondary antibodies (1:800;
Jackson ImmunoResearch Laboratories). Immunosignals were
visualized with 3,3-diaminobenzidine (Sigma-Aldrich).
The following primary antibodies were used: mouse
anti-TH antibody (1:500, Chemicon), mouse anti-ubiqutin
antibody (1:100, Santa Cruz Biotechnology), mouse anti-Parkin
antibody (1:100, Santa Cruz Biotechnology), mouse anti-
Flag antibody (1:100, Shanghai Genomics), rabbit anti-GFP
antibody (1:1000, Invitrogen), rabbit anti-α-synuclein (1:500,
Cell Signaling), mouse anti-phospho-α-synuclein (1:2000,
WAKO). Sections were imaged using either a cooled CCD
(DP72, Olympus) on a microscope (BX51; Olympus, Japan)
or a laser confocal microscope (Leica, Bensheim, Germany).
Data were obtained and processed using Adobe Photoshop 7.0
software (Adobe System).
Cell Culture and Transfection
Primary cortical neurons were cultured as described previously
(Martinoia et al., 2005). In brief, dissociated cortical tissue from
embryonic day 18 (E18) rat pups were digested with 0.125%
trypsin for 5 min at 37◦C and 2 × 106 neurons were transfected
with 4µg either pEGFP-C1 or pEGFP-C1-Hapln2 plasmids using
a Nucleofector R© II device (Amaxa). The neurons were seeded on
poly-L-lysine-coated plates in Neurobasal medium (Invitrogen)
containing B-27 (Invitrogen) and 2mM Glutamax (Invitrogen).
MES23.5 cells, a gift from Dr. Weidong Le (Crawford
et al., 1992), were seeded in poly-L-lysine (PLL, 10 ng/
ml, Sigma)-coated plates and were incubated in DMEM/F12
medium (Invitrogen), supplemented with 5% fetal bovine
serum (FBS), 2% Sato, 2mM glutamax (Invitrogen), 1%
penicillin/streptomycin (Invitrogen), and 0.1%NaHCO3 (Sigma-
Aldrich) at 37◦C in humidified air containing 5%CO2. HEK293T
cells were maintained in DMEM containing 10% FBS at 37◦C
in humidified air containing 5% CO2. For cell transfection
experiments, full-length human Hapln2 was subcloned into
mammalian expression vector either pEGFP-C1 or pcDNA3.1
(Invitrogen) to produce EGFP-tagged and myc-tagged Hapln2
constructs. MES23.5 cells were transfected with either pEGFP-
C1-Hapln2 or Flag-tagged Parkin, Hrd1 or Gp78 plasmids
using a Nucleofector R© II device (Amaxa). HEK293T cells
were transiently transfected with pEGFP-C1-Hapln2 plasmid in
accordance with a standard calcium phosphate protocol.
MTT Assay
The viability of MES23.5 cells was measured 24 h following
the transfection of Hapln2 plasmid using the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay as
described previously (Bakare et al., 2015). Briefly, MTT solution
(5 mg/ml) was added to the cells in 96-well plate containing
150 µl of DMEM and incubated for 4 h at 37◦C. DMSO
was then added after removal of the supernatant solution and
the absorbance was read on a microplate reader (Berthold
Technologies) at 570 nm.
Analysis of Apoptosis using Flow
Cytometry
The viability of MES23.5 cells was measured 24 and 48 h
following the transfection of Hapln2 plasmid using flow
cytometry assay. Briefly, MES23.5 cells transfected with pEGFP-
C1-Hapln2 plasmid were incubated with Alex Fluor 647
(KeyGEN BioTECH)-labeled Annexin and PI (Sigma-Aldrich)
for 10min in dark and analyzed immediately by MoFloTM XDP
(Beckman Coulter).
Statistical Analysis
Statistical analysis was performed using GraphPad software
(GraphPad Prism v5.0; GraphPad Software). The control group
was compared with the PD group or the treatment group using
student’s t-test. P< 0.05 was considered as significant in statistics.
RESULTS
Validation of the Hapln2 Antibody
To assess the specificity of Hapln2 antibody, we transfected
293T cells with pEGFP-C1-Hapln2 plasmid (Figure S1A) and
western blotting was performed using both anti-GFP antibody
and anti-Hapln2 antibody. It has been reported that the predicted
open reading frame of Hapln2 encoded a polypeptide of 340
amino acids containing one immunoglobulin (Ig) fold and two
PTR domains with an estimated molecular weight of 38 kDa
(Hirakawa et al., 2000). Western blot analysis of transfected
293T cell lysates showed that a band with the molecular
weight approximately 55 kDa, corresponding to EGFP-tagged
Hapln2, was detected using anti-Hapln2 antibody (Figure S1B).
The same band was also recognized by anti-GFP antibody
(Figure S1B), suggesting the anti-Hapln2 antibody is reliable
for Western blotting. Moreover, this antibody recognized a
band of approximately 48 kDa in the tissue lysates of mouse
and rat SN (Figure S1C). Given that Hapln2 is one of the
hyaluronan and proteoglycan binding link proteins (Spicer
et al., 2003), the discrepancy in molecular weight of Hapln2
between tissue and cell lysates may result from hyaluronic acid
modification.
Hapln2 Is Highly Expressed in DA Neurons
in the SN of Rat
There have been only a few studies investigating the expression
pattern of Hapln2 in the CNS (Hirakawa et al., 2000; Oohashi
et al., 2002). Thus, the precise expression pattern of Hapln2
mRNA in adult brain is not fully established. Using ISH,
we found a heterogeneous expression of Hapln2 hybridization
signals in adult rat brain, with the high expression levels in
both the pars compacta and pars reticulate of the SN (A9,
Figures 1A,B), ventral tagmental area (VTA, A10, Figure 1A),
olfactory bulb (Figure 1G), and red nucleus (Figure 1H). The
former three nuclei are known as DA neuron-enriched brain
regions. Robust hybridization signals were also seen in the
cerebellum, brain stem, and hippocampus (Figures 1C,D,F). In
contrast, relatively weak hybridization signals were observed
in the cerebral cortex (Figure 1E) and no marked expression
in the striatum (Figure 1I). These hybridization signals were
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specific for Hapln2, since there was no positive signal in negative
control using a sense probe as shown in Figures S2A–D,F,G,
except those in the pyramidal neurons in the hippocampus
(Figure S2E).
To further determine the association between Hapln2
and nigral DA neurons, Hapln2 ISH combined with
immunohistochemistry for TH was performed on adult rat
brain sections. It was revealed that Hapln2 hybridization
signals were highly localized to TH-positive neurons in the
SN (Figures 1J,K). These results suggest that Hapln2 is widely
expressed in adult brain with preferential expression in the
several brain regions including the SN.
FIGURE 1 | Hapln2 is highly expressed in various brain regions
including the substantia nigra of adult rat brain. Panels (A–H) show that
the Hapln2 hybridization signals are detected in various rat brain regions
including the substantia nigra (A,B) and ventral tagmental area (A), cerebellum
(C), brain stem (D), cerebral cortex (E), hippocampus (F), olfactory bulb (G),
and red nucleus (H). (I) Lower Hapln2 hybridization signals are seen in the
striatum. (J) Representative photomicrographs showing robust Hapln2
hybridization signals in TH-positive neurons in the substantia nigra (SN). Panel
(K) shows the enlarged images of the squared areas in J. Arrows indicate the
Hapln2 hybridization signals in the VTA and SNc (A,B). SNc, substantia nigra
pars compacta; SNr, substantia nigra pars reticulata. Scale
bars = 300µm.
Hapln2 Expression Is Upregulated in the
SN of PD Patients
Our previous quantitative proteomic analysis, which was based
on culture-derived isotope tags (CDIT) method and mass
spectrometry, revealed that Hapln2 was one of the proteins that
showed a marked increase in expression levels in the SN of the
PD patients compared with the healthy controls (Liu et al., 2015).
To validate whether the expression level of Hapln2 protein was
truly altered in PD, we quantitatively compared the expression of
Hapln2 protein in the SN in an independent cohort consisting of
three pairs of PD patients and age- and gender-matched healthy
controls using western blotting. Consistent with our previous
findings (Liu et al., 2015), there was a profound increase in the
expression of Hapln2 in the SN of patients with PD compared
with healthy control subjects (Figures 2A,B).
Hapln2 Expression Is Upregulated in the
SN of Rat PD Model
Next, we determined whether the expression levels of Hapln2
protein are altered in 6-OHDA-induced rat PD model in which
partial lesion of nigrostriatal DA pathway was achieved by
striatal infusion. qPCR analysis showed that at 2 weeks following
6-OHDA administration, mRNA levels of Hapln2 in the
lesioned SN were 1.79-fold higher than the control (Figure 3A).
Moreover, there was a marked increase in expression levels of
Hapln2 in the SN of 6-OHDA-treated rats compared with control
2 and 4 weeks post-lesioning (Figure 3B). These data were highly
consistent with the results obtained from the SN of patients with
PD (Figure 2). Taken together, these data suggest that remaining
nigral DA neurons in lesioned SN may produce more Hapln2
than control during neurodegeneration.
FIGURE 2 | Expression of Hapln2 protein is up-regulated in the
substantia nigra of patients with PD. (A) Western blotting of Hapln2 in the
SN of PD patients and healthy controls. (B) Quantitative data shown in (A).
Levels of Hapln2 were normalized to actin levels. Data are expressed as mean
± S.E.M. (n = 3). *P < 0.05 compared to control.
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FIGURE 3 | Expression of Hapln2 is up-regulated in the substantia nigra of rat PD model. (A) qPCR reveals the changes of Hapln2 mRNA levels in the SN of
rat 2 weeks following 6-OHDA treatment. Data are expressed as mean ± S.E.M. (n = 3). *P < 0.05. (B) Representative western blots showing Hapln2 expression in
the substantia nigra of rat 2 and 4 weeks after 6-OHDA infusion.
Overexpression of Hapln2 Reduces
MES23.5 Cell Viability
To evaluate the impact of Hapln2 overexpression to DA cells,
the MES23.5 cell viability was assessed using MTT assay
following transfection of the plasmids encoding either GFP-
Hapln2 or myc-tagged Hapln2 plasmids. It was found that the
viability of MES23.5 cell was markedly reduced in MES23.5 cells
overexpressing either GFP- or myc-tagged Hapln2 compared
with control group (Figure 4A). Moreover, flow cytometry
analysis showed that overexpression of Hapln2 resulted in
approximately four-fold increases in the percentage of both
Annexin V- and PI-positive cells or Annexin V-positive but PI-
negative cells 24 h after Hapln2 plasmid transfection, suggesting
that Hapln2 overexpression results in apoptosis or necrosis
(Figures 4B–E). Interestingly, at 48 h after the transfection,
apoptosis (Annexin V-positive/PI-negative cells) of MES23.5
cells transfected with Hapln2-GFP was more severe (GFP: 3.42
± 0.191% vs. Hapln2-GFP: 11.36± 0.63%, Figures 4B–E). While
there was no significant alteration in the percentage of Annexin
V-negative but PI-positive cells 24 or 48 h after Hapln2-GFP
transfection compared with control (Figure 4F). Accordingly,
the percentage of viable cells (both Annexin V- and PI-negative
cells) was decreased from 94.66 ± 0.35% to 83.24 ± 0.31% 24 h
after transfection and from 91.91 ± 1.84% to 74.24 ± 0.68% 48 h
after transfection, while there was no marked changes in control
over time (Figure 4G).
Moreover, we determined the influence of Hapln2
overexpression on MES23.5 cell viability in the presence
of neurotoxin 6-OHDA. Treatment of MES23.5 cells with
6-OHDA dramatically reduced their survival in a concentration-
dependent manner. We selected concentration of 50µM
6-OHDA for further experiments. At this concentration of
6-OHDA, there was 37% reduction of cell viability (Figure 4H).
Exposure of MES23.5 cells overexpressing Hapln2 to 50µM
6-OHDA for 24 h resulted in 31% reduction in cell viability
compared to those transfected with an empty vector (Figure 4I).
To further evaluate the potential impact of Hapln2 on neuronal
cell survival, we transfected primary cortical neurons with
an expression construct for Hapln2-GFP. Overexpression of
Hapln2-GFP resulted in marked decreases in the diameter of
tectal neuronal soma (GFP: 12.95 ± 0.1483 vs. Hapln2-GFP:
9.962 ± 0.1854µm) and the percentage of neurons bearing
neurites (GFP: 85.56 ± 1.20% vs. Hapln2-GFP: 22.75 ± 1.60%)
24 h after transfection (Figures 4J,K). These data suggest that
overexpression of Hapln2 is detrimental to DA neurons.
Overexpression of Hapln2 Promotes
Protein Aggregation
To further understand the potential function of Hapln2 on
DA degeneration, we examined the subcellular structures
in individual MES23.5 cells and primary cortical neurons
overexpressing GFP-Hapln2. Under basal conditions, the
pEGFP-transfected cells presented no GFP aggregates 24 h
post-transfection. However, significant elevations in protein
aggregates were detected in MES23.5 and primary neurons
transfected with GFP-Hapln2 plasmids (Figures 5A,B). To
elucidate the characteristics of aggregates formed, we conducted
immunostaining using antibodies against ubiquitin. It has been
widely recognized that ubiquitin-proteasome system (UPP)
is one of the main pathways for degradation of aggregated or
misfolded proteins in eukaryotic cells (Koshizuka et al., 2015;
Long et al., 2015). Ubiquitin is one of the components of Lewy
bodies, indicating the important role of UPP in PD (Cai et al.,
2015; Navarro-Yepes et al., 2015). It was shown that aggregated
Hapln2 protein was co-localized with ubiquitin (Figure 5C),
suggesting that the aggregated Hapln2 was ubiquitinated.
Consistent with these results, MG132 treatment also induced
profound upregulation of the exogenous GFP-tagged Hapln2
(Figures 5D,E), suggesting that the degradation of Hapln2 is
dependent on UPP.
E3 Ubiquitin Ligases Are Co-localized with
Hapln2 in Cytoplasmic Aggregates
E3 ubiquitin ligases (E3s) are known to play a key role in
determining substrate specificity and catalyzing the transfer of
ubiquitin from E2 enzymes to the substrate in the UPP (Soucy
et al., 2009; Metzger et al., 2012; Uchida and Kitagawa, 2015).
To determine whether E3 ubiquitin ligases are involved in
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FIGURE 4 | Over-expression of Hapln2 reduces the viability of MES23.5 cell and primary cortical neurons. (A–C) The viability of MES23.5 cell was evaluated
by MTT assay (A) or flow cytometry analysis (B,C) 24 or 48 h after transfection with Hapln2 plasmids. (D–G) Quantitative data shown in (B,C). (H) The survival ability
of MES23.5 cell after 6-OHDA treatment. (I) The viability of MES23.5 cell transfected with Hapln2 plasmids following 6-OHDA challenge. Data are expressed as mean
± S.E.M (n = 6 in A, n = 3 in D–H, n = 4 in I). (J) Representative photomicrographs showing the morphology of primary cortical neurons 24 h after GFP-Hapln2
plasmids transfection. Scale bar = 20µm. (K) Quantitative data of the neuronal soma diameter and the percentage of neurons bearing neurites in (J). Data are
expressed as mean ± S.E.M (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 5 | Hapln2 is associated with ubiquitin-proteasome pathway (UPP). (A) Confocal images of Hapln2 aggregates in MES23.5 cells transfected with
Hapln2-GFP plasmids. Scale bar = 10µm. (B) Representative photomicrographs showing Hapln2 aggregates in primary cortical neurons transfected with GFP-
Hapln2 plasmids. Scale bar = 10µm. (C) Immunofluorescent staining for ubituitin in MES23.5 cells transfected with Hapln2-GFP plasmids. Scale bar = 10µm. (D)
Expression levels of Hapln2-GFP was analyzed in MES23.5 cells transfected with the Hapln2-GFP plasmid at indicated times after MG132 (20µM) treatment. (E)
Quantitative data of Hapln2 expression in (D) (n = 4). *p < 0.05, ***p < 0.001.
the ubiquitination of Hapln2-containing protein aggregates, we
investigated the expression pattern of ubiquitin ligases Parkin,
Hrd1, and Gp78 in MES23.5 cells overexpressing GFP-Hapln2.
It was revealed that approximately 20% of the cells co-transfected
with GFP-Hapln2 and Parkin showed co-localization of Hapln2
with Parkin in intracellular aggregates (Figure 6A). Likewise,
similar percentage of co-transfected cells showed co-localization
of Hapln2 with either Hrd1 or Gp78 in the protein aggregates,
while there was only 3% of cells co-transfected with the plasmids
encoding GFP-Hapln2 and FLAG-empty vector showed Hapln2-
positive aggregates and none aggregates was seen in cells co-
transfected with both GFP and FLAG empty vectors which served
as negative controls (Figure 6A). These data suggest that Hapln2
may promote sequestration of E3 ligases by recruiting them into
the aggregates.
Aggregated Hapln2 Sequestrates Parkin
(C418R) and α-Synuclein
We then asked a question whether Hapln2 has relevance with
human mutant genes causing PD. It has been demonstrated that
the RING domains of Parkin is essential for its E3 ubiquitin
ligase activity and the mutation (C418R) in the RING domains
of Parkin resulted in the aggregation of Parkin (Gu et al., 2003).
Thus, we examined whether the Parkin mutant is involved in the
ubiquitination of Hapln2. Immunofluorescent staining showed
that Hapln2 was also co-localized with the C418R missense
mutant form of Parkin in insoluble aggregates in some of the
transfected cells (Figure 6B), indicating that Hapln2 is associated
with protein aggregation caused by Parkin mutation.
α-Synuclein is a major component of Lewy bodies, a key
pathological characteristic of PD (Zhang et al., 2005). We
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FIGURE 6 | Exogenous Hapln2-GFP is co-localized with E3 ubiquitin ligases and α-synuclein. (A) Immunofluorescent staining co-localization of Hapln2 and
E3 ubiquitin ligases including Parkin, Hrd1, Gp78 in vitro. Arrow heads point to the merged cells. (B) Immunofluorescent staining showing the co-localization of
Hapln2 with Parkin (C418R). (C,D) Representative micrographs showing co-localization of Hapln2-GFP and phosph-α-synuclein (C) or α-synuclein (D) in MES23.5
cells transfected with Hapln2-GFP plasmids. Arrows indicate the colocalization of Hapln2 and phospho-α-synuclein (C) or α-synuclein (D). Scale bars = 10µm. (E,F)
Expression levels of RIPA-soluble and urea-soluble protein fractions extracted from SN (E) and cerebellum (F). Data are expressed as mean ± S.E.M. (n = 3).
*p < 0.05.
examined whether the overexpressed Hapln2 is associated
with α-synuclein. It was found that exogenous Hapln2 was co-
localized with endogenous phospho-α-synuclein and α-synuclein
in the aggregates in MES23.5 cells (Figures 6C,D), suggesting
that Hapln2 overexpression perturbed the intracellular
distribution of α-synuclein. To further clarify the role of
Hapln2 in protein aggregation, we isolated the RIPA-soluble and
RIPA-insoluble protein fractions from the SN and cerebellum
of Hapln2 knockout mice. Western blotting analysis showed
that significant decreases in the ratio of insoluble to soluble α-
synuclein was observed in both the SN and cerebellum ofHapln2-
deficient mice compared with control (Figures 6E,F), suggesting
that absence of Hapln2 compromise α-synuclein-associated
protein aggregation. Taken together, these results indicate that
the upregulated Hapln2 protein may contribute to PD pathology
by enhancing α-synuclein accumulation in DA neurons.
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DISCUSSION
In the present study, we described Hapln2 expression pattern
in adult rat brain and, interestingly, the upregulation of Hapln2
expression levels in the SN of patients with PD as well as rat
PD model. Hapln2 overexpression resulted in the formation of
cytoplasmic aggregates in primary cortical neurons and MES23.5
cell. Moreover, Hapln2 overexpression led to a marked reduction
of DA cell viability and exacerbated 6-OHDA-induced loss of
MES23.5 cell viability. Hapln2 overexpression also promoted α-
synuclein accumulation in MES23.5 cell and ablation of Hapln2
resulted in a decrease in the levels of α-synuclein in insoluble
fraction in brain tissues. These findings highlight the importance
of Hapln2 as a novel factor contributing to neurodegeneration in
PD.
Expression of Hapln2 in Nigral DA Neurons
Previous studies have demonstrated that the Hapln2
immunosignals were primarily localized in myelinated fiber
tracts in the adult brain and were co-expressed with the versican
V2 isoform at the nodes of Ranvier (Oohashi et al., 2002).
These data imply that Hapln2 may play an important role in the
formation of an ion diffusion barrier at the nodes promoting
neuronal conduction. In the present study, we found that
Hapln2 mRNA is expressed in a variety of brain regions, with
moderate expression in the cerebral cortex, where is enriched
with myelinated axons from pyramidal neurons. This supports
the idea that Hapln2 may play an important role in the formation
of an ion diffusion barrier at the nodes in the myelinated neurons
as previously indicated. It is interesting to note, however, that
Hapln2 mRNA is also expressed in some of other brain regions,
where the neurons usually have no myelination, for example,
the dendate gyrus in the hippocampus and substantia nigra
(Figure 1). These data indicate that Hapln2 may play distinct
roles in these brain regions from what was previously reported.
Hapln2 As a New Contributor to PD
Pathology
We found in the present study that protein levels of Hapln2
were robustly upregulated in nigral tissue of PD patients
and PD animal models. To investigate the consequence of
upregulated expression of Hapln2, Hapln2 was overexpressed
in MES23.5 cells, a dopaminergic cell line. Exogenous Hapln2
appeared as cytoplasmic aggregates in MES23.5 cells, and the
aggregates were co-localized with ubiquitin, indicating the
possible relationship between Hapln2 and ubiquitin degradation
pathway. Degradation of a target protein by UPP requires a series
of reactions which involve three key enzymes including Ub-
activating enzyme (E1), Ub-conjugating enzyme (E2), and Ub-
ligase (E3) (Weissman, 2001; Papaevgeniou and Chondrogianni,
2014). Among these ubiquitin related enzymes, E3s play a
crucial role in catalyzing the ubiquitin chains on the specific
substrate (Long et al., 2015). Previous research has reported that
ubiquitination of misfolded proteins is also a common hallmark
of a variety of age-related neurodegenerative diseases including
PD (Zhang et al., 2005; Bhat et al., 2014; Hromadkova et al.,
2015; Squitieri and de Yebenes, 2015). And it has been reported
that dysfunction of UPP induced by proteasome inhibitors, such
as MG132 and epoxomicin, led to dopaminergic degeneration
in both cell cultures and animal models (Kikuchi et al., 2003;
Sun et al., 2006), indicating the importance of UPP in PD. In
the present study, MG132 treatment induced the upregulation of
exogenous Hapln2 in MES23.5 cells, indicating that Hapln2 may
be degraded by ubiquitin degradation pathway.
Our previous proteomics analysis revealed that the
upregulation of Hapln2 showed the highest fold change in
the brain of PD patients (Liu et al., 2015). These observations
along with the data shown in Figure 2 in the present study
strongly suggest a close correlation between Hapln2 and PD.
However, the biological role and significance of this change
remain to be clarified. Our data suggest that upregulation of
Hapln2 is associated with abnormal protein aggregation, based
on the observations that exogenous Hapln2 was co-localized
with the E3 ligases, including Parkin, Hrd1, and Gp78. Parkin
is a PD-associated gene which encodes an E3-ubiquitin ligase
(Kitada et al., 1998). The finding that exogenous Hapln2 was
colocalized with Parkin C418 suggests that dysfunction of
Parkin is associated with Hapln2 degradation. Another ubiquitin
ligase Hrd1 has been reported to promote the ubiquitination
and degradation of Parkin-associated endothelin receptor-like
receptor (Pael-R), which is an ER stress inducer contributing to
familial PD (Omura et al., 2013). Besides, Hrd1 could suppress
the neuronal cell death caused by 6-OHDA (Omura et al.,
2013), suggesting the potential role of Hrd1 in PD pathogenesis.
Earlier work also showed another E3 ubiquitin ligase Gp78 could
promote the degradation of misfolded protein regulated by Hrd1
(Zhang et al., 2015).
Given that LB is one of the hallmarks of PD pathology (Zhang
et al., 2005) and strong correlation between Hapln2 and the
“molecular signature” of LB such as α-synuclein and E3s shown
in the present study, we speculate that Hapln2 could be one
of components of LB. There is evidence that LB is consisted
of a heterogeneous mixture including lipids forming the core
of the inclusions and proteins mainly including neurofilament,
various proteasomal elements, and α-synuclein (Wakabayashi
et al., 2013; Araki et al., 2015; Power et al., 2015). Our result in
the present study showed that α-synuclein could be sequestered
by Hapln2 aggregates and Hapln2 deficiency altered the levels
of α-synuclein in insoluble fraction (Figure 6). Although there
is no direct pathological evidence that Hapln2 is a integral
constituent of LB in PD, Hapln2 has been recently shown to be
accumulated in the neurofibrillary tangle of Alzheimer’s brain
(Bandopadhyay, 2016), indicating that Hapln2 can be the part of
protein deposition process involved in pathogenesis of both AD
and PD. Future study is needed to determine the role of Hapln2
in the formation of LB.
In conclusion, as a novel brain specific-hyaluronan and
protoglycan link protein, the knowledge of the function
of Hapln2 in neurological diseases is still lacking. In the
present study, we have shown that Hapln2 was involved in
the pathogenesis of PD, which will not only promote our
understanding of the role of Hapln2 in the PD pathogenesis
but also provide new insights into pathogenesis of age-related
neurodegenerative disorders.
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Figure S1 | Verification of the specificity of Hapln2 antibody. (A)
Representative photomicrographs showing the expression pattern of Hapln2-GFP
in HEK293T cells transfected with Hapln2-GFP plasmids. (B) Western blot
analysis of cell lysates of 293T cells transfected with Hapln2-GFP plasmids using
anti-GFP and anti-Hapln2 antibodies. (C) Western blot analysis of tissue lysates of
the substantia nigra of adult rat using anti-Hapln2 antibody.
Figure S2 | Verification of the specificity of Hapln2 in situ hybridization
probe. Panels (A–G) show the hybridization signals of Hapln2 in ventral midbrain
(A), cerebral cortex (B), striatum (C), cerebellum (D), hippocampus (E), olfactory
bulb (F), and brain stem (G) of rat slices using a sense probe. Scale bar = 300µm.
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